Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genelux Corporation stock logo
GNLX
Genelux
$2.56
+2.4%		$2.59
$2.29
▼
$8.53
$113.11M0.59235,228 shs154,650 shs
Oncocyte Corp stock logo
IMDX
Oncocyte
$3.37
+2.7%		$4.08
$2.42
▼
$8.51
$107.34M1.8335,904 shs156,356 shs
MDNAF
Medicenna Therapeutics
$0.32
+1.7%		$0.30
$0.23
▼
$1.43
$28.67M1.9756,962 shs22,979 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.80
+0.9%		$0.82
$0.45
▼
$3.87
$110.40M0.69575,800 shs235,515 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genelux Corporation stock logo
GNLX
Genelux
-0.79%-0.79%-1.57%-17.49%-47.37%
Oncocyte Corp stock logo
IMDX
Oncocyte
-5.20%-5.48%-23.19%-35.43%+327,999,900.00%
MDNAF
Medicenna Therapeutics
0.00%+14.87%-8.02%+19.10%+31,059,900.00%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-2.48%-0.44%-9.23%+15.25%+61.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genelux Corporation stock logo
GNLX
Genelux
$2.56
+2.4%		$2.59
$2.29
▼
$8.53
$113.11M0.59235,228 shs154,650 shs
Oncocyte Corp stock logo
IMDX
Oncocyte
$3.37
+2.7%		$4.08
$2.42
▼
$8.51
$107.34M1.8335,904 shs156,356 shs
MDNAF
Medicenna Therapeutics
$0.32
+1.7%		$0.30
$0.23
▼
$1.43
$28.67M1.9756,962 shs22,979 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.80
+0.9%		$0.82
$0.45
▼
$3.87
$110.40M0.69575,800 shs235,515 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genelux Corporation stock logo
GNLX
Genelux
-0.79%-0.79%-1.57%-17.49%-47.37%
Oncocyte Corp stock logo
IMDX
Oncocyte
-5.20%-5.48%-23.19%-35.43%+327,999,900.00%
MDNAF
Medicenna Therapeutics
0.00%+14.87%-8.02%+19.10%+31,059,900.00%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-2.48%-0.44%-9.23%+15.25%+61.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genelux Corporation stock logo
GNLX
Genelux
2.80
Moderate Buy$18.00603.13% Upside
Oncocyte Corp stock logo
IMDX
Oncocyte
2.33
Hold$10.50211.57% Upside
MDNAF
Medicenna Therapeutics
2.00
HoldN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.83
Moderate Buy$8.75995.12% Upside

Current Analyst Ratings Breakdown

Latest MDNAF, GNLX, IMDX, and RANI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2026
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/21/2026
Oncocyte Corp stock logo
IMDX
Oncocyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/16/2026
Genelux Corporation stock logo
GNLX
Genelux
Lucid Cap Mkts logo
Lucid Cap Mkts
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/26/2026
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/21/2026
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/18/2026
Genelux Corporation stock logo
GNLX
Genelux
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSpeculative Buy
8/18/2026
Oncocyte Corp stock logo
IMDX
Oncocyte
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
8/18/2026
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
7/17/2026
Genelux Corporation stock logo
GNLX
Genelux
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genelux Corporation stock logo
GNLX
Genelux
$8K14,478.40N/AN/A$0.30 per share8.53
Oncocyte Corp stock logo
IMDX
Oncocyte
$4.05M27.23N/AN/A($1.10) per share-3.06
MDNAF
Medicenna Therapeutics
N/AN/AN/AN/A$0.02 per shareN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$4.88M22.84N/AN/A$0.34 per share2.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genelux Corporation stock logo
GNLX
Genelux
-$32.15M-$0.86N/AN/AN/AN/A-205.85%-138.79%11/4/2026 (Estimated)
Oncocyte Corp stock logo
IMDX
Oncocyte
-$50.22M-$1.49N/AN/AN/A-2,955.63%N/A-107.52%N/A
MDNAF
Medicenna Therapeutics
-$13.32M-$0.16N/AN/AN/AN/A-1.38%-0.66%N/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$29.67M-$0.27N/AN/AN/AN/A-104.60%-65.17%11/5/2026 (Estimated)

Latest MDNAF, GNLX, IMDX, and RANI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.05N/AN/AN/A$1.28 millionN/A
11/4/2026Q3 2026
Genelux Corporation stock logo
GNLX
Genelux
-$0.20N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Genelux Corporation stock logo
GNLX
Genelux
-$0.1967-$0.21-$0.0133-$0.21N/AN/A
8/13/2026Q2 2026
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.05-$0.04+$0.01-$0.04$0.93 million$1.71 million
8/10/2026Q2 2026
Oncocyte Corp stock logo
IMDX
Oncocyte
N/A-$0.23N/A-$0.31N/A$0.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Genelux Corporation stock logo
GNLX
Genelux
N/AN/AN/AN/AN/A
Oncocyte Corp stock logo
IMDX
Oncocyte
N/AN/AN/AN/AN/A
MDNAF
Medicenna Therapeutics
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genelux Corporation stock logo
GNLX
Genelux
N/A
2.39
2.39
Oncocyte Corp stock logo
IMDX
Oncocyte
N/A
2.00
1.98
MDNAF
Medicenna Therapeutics
N/A
1.25
1.25
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/A
5.31
5.31

Institutional Ownership

CompanyInstitutional Ownership
Genelux Corporation stock logo
GNLX
Genelux
37.33%
Oncocyte Corp stock logo
IMDX
Oncocyte
55.35%
MDNAF
Medicenna Therapeutics
35.85%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%

Insider Ownership

CompanyInsider Ownership
Genelux Corporation stock logo
GNLX
Genelux
7.50%
Oncocyte Corp stock logo
IMDX
Oncocyte
2.21%
MDNAF
Medicenna Therapeutics
33.10%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
26.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genelux Corporation stock logo
GNLX
Genelux
2645.25 million41.85 millionNot Optionable
Oncocyte Corp stock logo
IMDX
Oncocyte
5832.72 million32.00 millionN/A
MDNAF
Medicenna Therapeutics
2092.30 million61.75 millionN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
69139.40 million102.14 millionOptionable

Recent News About These Companies

Rani Therapeutics Holdings, Inc. Announces Acceptance Of RaniPill Capsule Platform Technology Into U.S. Food And Drug Administration Emerging Technology Program
October 6 at 2:41 PM  |  marketscreener.comM
Rani Therapeutics' RaniPill Accepted Into FDA Emerging Technology Program
October 5, 2026  |  rttnews.comhttps://www.rttnews.com/3696565/rani-therapeutics-ranipill-accepted-into-fda-emerging-technology-program.aspx
FDA accepts Rani Therapeutics' RaniPill platform into emerging tech program
October 5, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/FDA+accepts+Rani+Therapeutics+RaniPill+platform+into+emerging+tech+program/27146016.html
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374470/0/en/rani-therapeutics-announces-acceptance-into-u-s-fda-s-emerging-technology-program-etp.html
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Brokerages
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-rani-therapeutics-holdings-inc-nasdaq-rani-receives-consensus-rating-of-moderate-buy-from-brokerages-2026-09-23/
Rani Therapeutics to Participate in Upcoming September Conferences
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357608/0/en/rani-therapeutics-to-participate-in-upcoming-september-conferences.html
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Sanofi (OtherSNYNF)
August 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SNYNF/pressreleases/4015435/analysts-offer-insights-on-healthcare-companies-rani-therapeutics-holdings-rani-and-sanofi-othersnynf/
Canaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
August 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/KYMR-Q/pressreleases/3715766/canaccord-genuity-sticks-to-its-buy-rating-for-kymera-therapeutics-kymr/
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344933/0/en/rani-therapeutics-reports-second-quarter-2026-financial-results-provides-corporate-update.html
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/rani-therapeutics-to-participate-in-the-canaccord-genuity-46th-annual-growth-conference-1036435450
Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair
August 4, 2026  |  quiverquant.comQ
Rani Therapeutics (NASDAQ:RANI) CEO Talat Imran Sells 8,014 Shares of Stock
July 29, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rani-insider-buying-and-selling-2026-07-29/
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3330091/0/en/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327637/0/en/rani-therapeutics-announces-positive-initial-phase-1a-data-for-rt-114-for-the-treatment-of-obesity-with-oral-bioavailability-exceeding-matched-subcutaneous-dosing.html
Rani Therapeutics Holdings (RANI) Declines 7.95%, Testing Key Support at $0.60 - Strangle Setup
July 14, 2026  |  donanimhaber.comD
Rani Therapeutics Holdings Inc - Ordinary Shares Class A
July 13, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/rani-rani-therapeutics-holdings-inc-ordinary-shares-class-a
Rani Therapeutics enters R&D collaboration with PegBio to expand obesity pipeline across multiple novel candidates
July 13, 2026  |  pharmabiz.comP
Why Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration?
July 10, 2026  |  kalkinemedia.comK
China's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani Therapeutics
July 10, 2026  |  yicaiglobal.comY
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
July 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/09/3325193/0/en/rani-therapeutics-announces-research-and-development-collaboration-with-pegbio-to-expand-obesity-pipeline-across-multiple-novel-candidates.html
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
June 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/29/3318896/0/en/rani-therapeutics-appoints-nicholas-maestas-as-chief-financial-officer.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genelux stock logo

Genelux NASDAQ:GNLX

$2.56 +0.06 (+2.40%)
Closing price 04:00 PM Eastern
Extended Trading
$2.56 +0.00 (+0.20%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Oncocyte stock logo

Oncocyte NASDAQ:IMDX

$3.37 +0.09 (+2.74%)
Closing price 04:00 PM Eastern
Extended Trading
$3.37 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Medicenna Therapeutics OTCMKTS:MDNAF

$0.32 +0.01 (+1.74%)
As of 03:20 PM Eastern

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.80 +0.01 (+0.88%)
Closing price 04:00 PM Eastern
Extended Trading
$0.79 -0.01 (-1.25%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas